Eli Lilly and Company (LLY) has redefined the boundaries of the pharmaceutical industry, emerging as the first healthcare entity to surpass a $1 trillion market capitalization. As of February 2026, the company stands at the vanguard of a metabolic revolution, driven by its incretin-based therapies, Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (tirzepatide) for obesity. The fiscal year 2025 was transformative, characterized by a 45% year-over-year revenue surge to $65.2 billion, underscoring the voracious global demand for GLP-1/GIP dual agonists.1

However, this commercial ascendancy coincides with a period of intense geopolitical and regulatory volatility. The inauguration of the Trump Administration in 2025 has introduced a new paradigm of "Most-Favored-Nation" (MFN) drug pricing and the launch of the federal direct-to-consumer  ...